U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Peripheral Primitive Neuroectodermal Tumor

MedGen UID:
1639124
•Concept ID:
C4684863
•
Neoplastic Process

Definition

Peripheral primitive neuroectodermal tumor that does not respond to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Peripheral Primitive Neuroectodermal Tumor

Professional guidelines

PubMed

Evolution and contemporary role of metronomic chemotherapy in the treatment of neuroblastoma.
Chou SW, Chang HH
Cancer Lett 2024 Apr 28;588:216617. Epub 2024 Feb 2 doi: 10.1016/j.canlet.2024.216617. PMID: 38311055
Pain mitigation and management strategies for anti-GD2 infusions: An expert consensus.
Nysom K, Morad AG, Rafael MS, Zier J, Marachelian A, Watt T, Morgenstern DA
Pediatr Blood Cancer 2023 May;70(5):e30217. Epub 2023 Feb 11 doi: 10.1002/pbc.30217. PMID: 36772891
Contemporary approach to diagnosis and treatment of neuroblastoma.
Charron M
Q J Nucl Med Mol Imaging 2013 Mar;57(1):40-52. PMID: 23474634

Recent clinical studies

Etiology

GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.
Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, Mastronuzzi A, Cefalo MG, Pagliara D, Amicucci M, Li Pira G, Leone G, Bertaina V, Sinibaldi M, Di Cecca S, Guercio M, Abbaszadeh Z, Iaffaldano L, Gunetti M, Iacovelli S, Bugianesi R, Macchia S, Algeri M, Merli P, Galaverna F, Abbas R, Garganese MC, Villani MF, Colafati GS, Bonetti F, Rabusin M, Perruccio K, Folsi V, Quintarelli C, Locatelli F; Precision Medicine Team–IRCCS Ospedale Pediatrico Bambino Gesù
N Engl J Med 2023 Apr 6;388(14):1284-1295. doi: 10.1056/NEJMoa2210859. PMID: 37018492
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
Goldsmith KC, Park JR, Kayser K, Malvar J, Chi YY, Groshen SG, Villablanca JG, Krytska K, Lai LM, Acharya PT, Goodarzian F, Pawel B, Shimada H, Ghazarian S, States L, Marshall L, Chesler L, Granger M, Desai AV, Mody R, Morgenstern DA, Shusterman S, Macy ME, Pinto N, Schleiermacher G, Vo K, Thurm HC, Chen J, Liyanage M, Peltz G, Matthay KK, Berko ER, Maris JM, Marachelian A, Mossé YP
Nat Med 2023 May;29(5):1092-1102. Epub 2023 Apr 3 doi: 10.1038/s41591-023-02297-5. PMID: 37012551Free PMC Article
Advancing therapy for neuroblastoma.
Qiu B, Matthay KK
Nat Rev Clin Oncol 2022 Aug;19(8):515-533. Epub 2022 May 25 doi: 10.1038/s41571-022-00643-z. PMID: 35614230
High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes.
DuBois SG, Macy ME, Henderson TO
Am Soc Clin Oncol Educ Book 2022 Apr;42:1-13. doi: 10.1200/EDBK_349783. PMID: 35522915
Recent advances in the developmental origin of neuroblastoma: an overview.
Ponzoni M, Bachetti T, Corrias MV, Brignole C, Pastorino F, Calarco E, Bensa V, Giusto E, Ceccherini I, Perri P
J Exp Clin Cancer Res 2022 Mar 11;41(1):92. doi: 10.1186/s13046-022-02281-w. PMID: 35277192Free PMC Article

Diagnosis

Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.
Oesterheld J, Ferguson W, Kraveka JM, Bergendahl G, Clinch T, Lorenzi E, Berry D, Wada RK, Isakoff MS, Eslin DE, Brown VI, Roberts W, Zage P, Harrod VL, Mitchell DS, Hanson D, Saulnier Sholler GL
J Clin Oncol 2024 Jan 1;42(1):90-102. Epub 2023 Oct 26 doi: 10.1200/JCO.22.02875. PMID: 37883734Free PMC Article
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
Goldsmith KC, Park JR, Kayser K, Malvar J, Chi YY, Groshen SG, Villablanca JG, Krytska K, Lai LM, Acharya PT, Goodarzian F, Pawel B, Shimada H, Ghazarian S, States L, Marshall L, Chesler L, Granger M, Desai AV, Mody R, Morgenstern DA, Shusterman S, Macy ME, Pinto N, Schleiermacher G, Vo K, Thurm HC, Chen J, Liyanage M, Peltz G, Matthay KK, Berko ER, Maris JM, Marachelian A, Mossé YP
Nat Med 2023 May;29(5):1092-1102. Epub 2023 Apr 3 doi: 10.1038/s41591-023-02297-5. PMID: 37012551Free PMC Article
High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes.
DuBois SG, Macy ME, Henderson TO
Am Soc Clin Oncol Educ Book 2022 Apr;42:1-13. doi: 10.1200/EDBK_349783. PMID: 35522915
Theranostics in Neuroblastoma.
Rafael MS, Cohen-Gogo S, Irwin MS, Vali R, Shammas A, Morgenstern DA
PET Clin 2021 Jul;16(3):419-427. doi: 10.1016/j.cpet.2021.03.006. PMID: 34053585
Gangliosides and Neuroblastomas.
Schengrund CL
Int J Mol Sci 2020 Jul 27;21(15) doi: 10.3390/ijms21155313. PMID: 32726962Free PMC Article

Therapy

GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.
Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, Mastronuzzi A, Cefalo MG, Pagliara D, Amicucci M, Li Pira G, Leone G, Bertaina V, Sinibaldi M, Di Cecca S, Guercio M, Abbaszadeh Z, Iaffaldano L, Gunetti M, Iacovelli S, Bugianesi R, Macchia S, Algeri M, Merli P, Galaverna F, Abbas R, Garganese MC, Villani MF, Colafati GS, Bonetti F, Rabusin M, Perruccio K, Folsi V, Quintarelli C, Locatelli F; Precision Medicine Team–IRCCS Ospedale Pediatrico Bambino Gesù
N Engl J Med 2023 Apr 6;388(14):1284-1295. doi: 10.1056/NEJMoa2210859. PMID: 37018492
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
Goldsmith KC, Park JR, Kayser K, Malvar J, Chi YY, Groshen SG, Villablanca JG, Krytska K, Lai LM, Acharya PT, Goodarzian F, Pawel B, Shimada H, Ghazarian S, States L, Marshall L, Chesler L, Granger M, Desai AV, Mody R, Morgenstern DA, Shusterman S, Macy ME, Pinto N, Schleiermacher G, Vo K, Thurm HC, Chen J, Liyanage M, Peltz G, Matthay KK, Berko ER, Maris JM, Marachelian A, Mossé YP
Nat Med 2023 May;29(5):1092-1102. Epub 2023 Apr 3 doi: 10.1038/s41591-023-02297-5. PMID: 37012551Free PMC Article
Advancing therapy for neuroblastoma.
Qiu B, Matthay KK
Nat Rev Clin Oncol 2022 Aug;19(8):515-533. Epub 2022 May 25 doi: 10.1038/s41571-022-00643-z. PMID: 35614230
High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes.
DuBois SG, Macy ME, Henderson TO
Am Soc Clin Oncol Educ Book 2022 Apr;42:1-13. doi: 10.1200/EDBK_349783. PMID: 35522915
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis.
Heczey A, Courtney AN, Montalbano A, Robinson S, Liu K, Li M, Ghatwai N, Dakhova O, Liu B, Raveh-Sadka T, Chauvin-Fleurence CN, Xu X, Ngai H, Di Pierro EJ, Savoldo B, Dotti G, Metelitsa LS
Nat Med 2020 Nov;26(11):1686-1690. Epub 2020 Oct 12 doi: 10.1038/s41591-020-1074-2. PMID: 33046868

Prognosis

Advancing therapy for neuroblastoma.
Qiu B, Matthay KK
Nat Rev Clin Oncol 2022 Aug;19(8):515-533. Epub 2022 May 25 doi: 10.1038/s41571-022-00643-z. PMID: 35614230
High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes.
DuBois SG, Macy ME, Henderson TO
Am Soc Clin Oncol Educ Book 2022 Apr;42:1-13. doi: 10.1200/EDBK_349783. PMID: 35522915
Gangliosides and Neuroblastomas.
Schengrund CL
Int J Mol Sci 2020 Jul 27;21(15) doi: 10.3390/ijms21155313. PMID: 32726962Free PMC Article
Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.
Mody R, Yu AL, Naranjo A, Zhang FF, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Hank JA, Felder M, Birstler J, Sondel PM, Asgharzadeh S, Glade-Bender J, Katzenstein H, Maris JM, Park JR, Bagatell R
J Clin Oncol 2020 Jul 1;38(19):2160-2169. Epub 2020 Apr 28 doi: 10.1200/JCO.20.00203. PMID: 32343642Free PMC Article
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R
Lancet Oncol 2017 Jul;18(7):946-957. Epub 2017 May 23 doi: 10.1016/S1470-2045(17)30355-8. PMID: 28549783Free PMC Article

Clinical prediction guides

B7-H3 in Brain Malignancies: Immunology and Immunotherapy.
Guo X, Chang M, Wang Y, Xing B, Ma W
Int J Biol Sci 2023;19(12):3762-3780. Epub 2023 Jul 24 doi: 10.7150/ijbs.85813. PMID: 37564196Free PMC Article
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.
Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, Mastronuzzi A, Cefalo MG, Pagliara D, Amicucci M, Li Pira G, Leone G, Bertaina V, Sinibaldi M, Di Cecca S, Guercio M, Abbaszadeh Z, Iaffaldano L, Gunetti M, Iacovelli S, Bugianesi R, Macchia S, Algeri M, Merli P, Galaverna F, Abbas R, Garganese MC, Villani MF, Colafati GS, Bonetti F, Rabusin M, Perruccio K, Folsi V, Quintarelli C, Locatelli F; Precision Medicine Team–IRCCS Ospedale Pediatrico Bambino Gesù
N Engl J Med 2023 Apr 6;388(14):1284-1295. doi: 10.1056/NEJMoa2210859. PMID: 37018492
Anlotinib Induces a T Cell-Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma.
Su Y, Luo B, Lu Y, Wang D, Yan J, Zheng J, Xiao J, Wang Y, Xue Z, Yin J, Chen P, Li L, Zhao Q
Clin Cancer Res 2022 Feb 15;28(4):793-809. doi: 10.1158/1078-0432.CCR-21-2241. PMID: 34844980Free PMC Article
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis.
Heczey A, Courtney AN, Montalbano A, Robinson S, Liu K, Li M, Ghatwai N, Dakhova O, Liu B, Raveh-Sadka T, Chauvin-Fleurence CN, Xu X, Ngai H, Di Pierro EJ, Savoldo B, Dotti G, Metelitsa LS
Nat Med 2020 Nov;26(11):1686-1690. Epub 2020 Oct 12 doi: 10.1038/s41591-020-1074-2. PMID: 33046868
Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.
Mody R, Yu AL, Naranjo A, Zhang FF, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Hank JA, Felder M, Birstler J, Sondel PM, Asgharzadeh S, Glade-Bender J, Katzenstein H, Maris JM, Park JR, Bagatell R
J Clin Oncol 2020 Jul 1;38(19):2160-2169. Epub 2020 Apr 28 doi: 10.1200/JCO.20.00203. PMID: 32343642Free PMC Article

Recent systematic reviews

A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma.
Herd F, Basta NO, McNally RJQ, Tweddle DA
Eur J Cancer 2019 Apr;111:50-58. Epub 2019 Feb 26 doi: 10.1016/j.ejca.2018.12.032. PMID: 30822684Free PMC Article
A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma.
Wilson JS, Gains JE, Moroz V, Wheatley K, Gaze MN
Eur J Cancer 2014 Mar;50(4):801-15. Epub 2013 Dec 12 doi: 10.1016/j.ejca.2013.11.016. PMID: 24333097

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...